Advertisement
Screener

PRECIGEN, INC. (PGEN) Increase (Decrease) in Accounts Payable, Trade

2.8 / 5 stars · 68/120 Roast Me

PRECIGEN, INC. Increase (Decrease) in Accounts Payable, Trade

PRECIGEN, INC. (PGEN) reported Increase (Decrease) in Accounts Payable, Trade of -$6.67 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsPayableTrade · last filed 2026-08-04

  • PRECIGEN, INC. increase (decrease) in accounts payable, trade for the quarter ending 2026-06-30 was $2.84M, a 254.43% increase year-over-year.
  • PRECIGEN, INC. increase (decrease) in accounts payable, trade for the quarter ending 2026-03-31 was -$9.51M.
  • PRECIGEN, INC. increase (decrease) in accounts payable, trade for the quarter ending 2025-12-31 was $6.54M.
  • PRECIGEN, INC. increase (decrease) in accounts payable, trade for the quarter ending 2025-09-30 was $1.55M.
  • PRECIGEN, INC. increase (decrease) in accounts payable, trade for fiscal 2025 was $8.77M, a 466.04% increase from fiscal 2024.
  • PRECIGEN, INC. increase (decrease) in accounts payable, trade for fiscal 2024 was $1.55M.
  • PRECIGEN, INC. increase (decrease) in accounts payable, trade for fiscal 2023 was -$2.42M, a 738.79% decline from fiscal 2022.
  • PRECIGEN, INC. increase (decrease) in accounts payable, trade for fiscal 2022 was $379.00K, a 9.76% decline from fiscal 2021.
Period endIncrease (Decrease) in Accounts Payable, Trade 3 monthIncrease (Decrease) in Accounts Payable, Trade 6 monthIncrease (Decrease) in Accounts Payable, Trade 6 month as first filedIncrease (Decrease) in Accounts Payable, Trade 9 monthIncrease (Decrease) in Accounts Payable, Trade 12 month
2026-06-30$2.84M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
-$6.67M
10-Q · filed 2026-08-04
-$138.00K
derived: sum of 3 quarters · filed 2026-08-04
$1.41M
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31-$9.51M
10-Q · filed 2026-05-13
-$2.98M
derived: sum of 2 quarters · filed 2026-05-13
-$1.43M
derived: sum of 3 quarters · filed 2026-05-13
-$628.00K
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31$6.54M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
$8.08M
derived: sum of 2 quarters · filed 2026-03-25
$8.88M
derived: sum of 3 quarters · filed 2026-08-04
$8.77M
10-K · filed 2026-03-25
2025-09-30$1.55M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
$2.35M
derived: sum of 2 quarters · filed 2026-08-04
$2.23M
10-Q · filed 2025-11-13
$1.44M
derived: sum of 4 quarters · filed 2026-08-04
2025-06-30$801.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
$684.00K
10-Q · filed 2026-08-04
-$104.00K
derived: sum of 3 quarters · filed 2026-08-04
-$945.00K
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31-$117.00K
10-Q · filed 2026-05-13
-$905.00K
derived: sum of 2 quarters · filed 2026-05-13
-$1.75M
derived: sum of 3 quarters · filed 2026-05-13
-$1.22M
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31-$788.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
-$1.63M
derived: sum of 2 quarters · filed 2026-03-25
-$1.10M
derived: sum of 3 quarters · filed 2026-03-25
$1.55M
10-K · filed 2026-03-25
2024-09-30-$841.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
-$316.00K
derived: sum of 2 quarters · filed 2025-11-13
$2.34M
10-Q · filed 2025-11-13
$1.68M
derived: sum of 4 quarters · filed 2026-03-25
2024-06-30$525.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12
$3.18M
10-Q · filed 2025-08-12
$2.52M
derived: sum of 3 quarters · filed 2026-03-25
$2.29M
derived: sum of 4 quarters · filed 2026-03-25
2024-03-31$2.65M
10-Q · filed 2025-05-14
$1.99M
derived: sum of 2 quarters · filed 2026-03-25
$1.77M
derived: sum of 3 quarters · filed 2026-03-25
$481.00K
derived: sum of 4 quarters · filed 2026-03-25
2023-12-31-$662.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
-$885.00K
derived: sum of 2 quarters · filed 2026-03-25
-$2.17M
derived: sum of 3 quarters · filed 2026-03-25
-$2.42M
10-K · filed 2026-03-25
2023-09-30-$223.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
-$1.51M
derived: sum of 2 quarters · filed 2024-11-14
-$1.76M
10-Q · filed 2024-11-14
-$2.11M
derived: sum of 4 quarters · filed 2025-03-19
2023-06-30-$1.29M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14
-$1.54M
10-Q · filed 2024-08-14
-$1.54M
10-Q · filed 2023-08-09
-$1.89M
derived: sum of 3 quarters · filed 2025-03-19
-$194.00K
derived: sum of 4 quarters · filed 2025-03-19
2023-03-31-$249.00K
10-Q · filed 2024-05-14
-$598.00K
derived: sum of 2 quarters · filed 2025-03-19
$1.09M
derived: sum of 3 quarters · filed 2025-03-19
$718.00K
derived: sum of 4 quarters · filed 2025-03-19
2022-12-31-$349.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19
$1.34M
derived: sum of 2 quarters · filed 2025-03-19
$967.00K
derived: sum of 3 quarters · filed 2025-03-19
$379.00K
10-K · filed 2025-03-19
2022-09-30$1.69M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
$1.32M
derived: sum of 2 quarters · filed 2023-11-09
$728.00K
10-Q · filed 2023-11-09
$1.83M
derived: sum of 4 quarters · filed 2024-03-19
2022-06-30-$375.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09
-$963.00K
10-Q · filed 2023-08-09
$135.00K
derived: sum of 3 quarters · filed 2024-03-19
-$1.06M
derived: sum of 4 quarters · filed 2024-03-19
2022-03-31-$588.00K
10-Q · filed 2023-05-10
$510.00K
derived: sum of 2 quarters · filed 2024-03-19
-$690.00K
derived: sum of 3 quarters · filed 2024-03-19
$21.00K
derived: sum of 4 quarters · filed 2024-03-19
2021-12-31$1.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19
-$102.00K
derived: sum of 2 quarters · filed 2024-03-19
$609.00K
derived: sum of 3 quarters · filed 2024-03-19
$420.00K
10-K · filed 2024-03-19
2021-09-30-$1.20M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
-$489.00K
derived: sum of 2 quarters · filed 2022-11-09
-$678.00K
10-Q · filed 2022-11-09
-$219.00K
derived: sum of 4 quarters · filed 2023-03-06
2021-06-30$711.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08
$522.00K
10-Q · filed 2022-08-08
$981.00K
derived: sum of 3 quarters · filed 2023-03-06
$1.38M
derived: sum of 4 quarters · filed 2023-03-06
2021-03-31-$189.00K
10-Q · filed 2022-05-09
$270.00K
derived: sum of 2 quarters · filed 2023-03-06
$669.00K
derived: sum of 3 quarters · filed 2023-03-06
-$369.00K
derived: sum of 4 quarters · filed 2023-03-06
2020-12-31$459.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06
$858.00K
derived: sum of 2 quarters · filed 2023-03-06
-$180.00K
derived: sum of 3 quarters · filed 2023-03-06
-$1.10M
10-K · filed 2023-03-06
2020-09-30$399.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08
-$639.00K
derived: sum of 2 quarters · filed 2021-11-08
-$1.56M
10-Q · filed 2021-11-08
-$2.47M
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30-$1.04M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09
-$1.96M
10-Q · filed 2021-08-09
-$2.87M
derived: sum of 3 quarters · filed 2022-03-01
-$3.62M
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31-$917.00K
10-Q · filed 2021-05-10
-$1.83M
derived: sum of 2 quarters · filed 2022-03-01
-$2.58M
derived: sum of 3 quarters · filed 2022-03-01
-$5.03M
derived: sum of 4 quarters · filed 2022-03-01
2019-12-31-$917.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
-$1.66M
derived: sum of 2 quarters · filed 2022-03-01
-$4.11M
derived: sum of 3 quarters · filed 2022-03-01
-$5.35M
10-K · filed 2022-03-01
2019-09-30-$746.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09
-$3.19M
derived: sum of 2 quarters · filed 2020-11-09
-$4.43M
10-Q · filed 2020-11-09
2019-06-30-$2.45M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10
-$3.69M
10-Q · filed 2020-08-10
2019-03-31-$1.24M
10-Q · filed 2020-05-11
2018-12-31$4.68M
10-K · filed 2021-03-01
2017-12-31-$3.40M
10-K · filed 2020-03-02

Similar stocks

Stock NameCountryMarket CapPE Ratio
NewAmsterdam Pharma Co N.V. (NAMS)$2.719B-15.37
MBX Biosciences, Inc. (MBX)United States$2.664B-25.36
Disc Medicine, Inc. (IRON)United States$2.553B-11.40
Immunome Inc. (IMNM)United States$2.538B-9.45
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
Dyne Therapeutics, Inc. (DYN)United States$3.084B-7.09
SELLAS Life Sciences Group, Inc. (SLS)United States$2.420B-91.87
uniQure N.V. (QURE)$2.416B-4.93
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67